Skip to main content

Remote Job Finders (RJF)

Adaptimmune Raises ‘Substantial Doubt’ About Business Despite First-in-Class T Cell Therapy

Adaptimmune is rolling out its T cell therapy Tecelra for synovial sarcoma, recording $1.2 million in sales since its approval in August 2024. Nevertheless, it is pausing development of two oncology assets to save money.

Sanofi Commits up to $1.9B for Dren Bio’s Bispecific Antibody for Autoimmune Disease

The deal is the latest in a series of Sanofi investments in its immunology portfolio. According to Sanfoi, DR-0201 can achieve deep B cell depletion, giving it the potential to reset the immune system.

Settling for Less: Biopharma Professionals Taking Jobs They’re Overqualified For

Nearly half of BioSpace poll respondents recently took a biopharma job they were overqualified for, a finding that didn’t surprise a talent acquisition expert, who said it’s become much more likely to happen.
Scroll to top